Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Disparities along the glioblastoma clinical trials landscape.

Ludmir EB, Mandel JJ, McAleer MF, de Groot JF.

Neuro Oncol. 2018 Nov 26. doi: 10.1093/neuonc/noy176. [Epub ahead of print] No abstract available.

PMID:
30476295
2.

Genomic landscape of glioblastoma and the potential clinical utility.

Wang CJ, Choe KS.

CNS Oncol. 2014 May;3(3):169-72. doi: 10.2217/cns.14.15. No abstract available.

3.

Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.

Kim JY, Gatenby RA.

Methods Mol Biol. 2017;1513:61-81. Review.

PMID:
27807831
4.

The integrated landscape of driver genomic alterations in glioblastoma.

Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, Danussi C, Dolgalev I, Porrati P, Pellegatta S, Heguy A, Gupta G, Pisapia DJ, Canoll P, Bruce JN, McLendon RE, Yan H, Aldape K, Finocchiaro G, Mikkelsen T, Privé GG, Bigner DD, Lasorella A, Rabadan R, Iavarone A.

Nat Genet. 2013 Oct;45(10):1141-9. doi: 10.1038/ng.2734. Epub 2013 Aug 5.

5.

Toward precision medicine in glioblastoma: the promise and the challenges.

Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM.

Neuro Oncol. 2015 Aug;17(8):1051-63. doi: 10.1093/neuonc/nov031. Epub 2015 May 1. Review.

6.

Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma.

Rhome R, Fisher R, Hormigo A, Parikh RR.

J Neurooncol. 2016 Jun;128(2):241-50. doi: 10.1007/s11060-016-2101-5. Epub 2016 Mar 12.

PMID:
26970981
7.

Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights.

Ng K, Kim R, Kesari S, Carter B, Chen CC.

J Neurooncol. 2012 Mar;107(1):1-12. doi: 10.1007/s11060-011-0714-2. Epub 2011 Oct 16. Review.

PMID:
22002595
8.

Immunotherapy in glioblastoma: emerging options in precision medicine.

Hodges TR, Ferguson SD, Heimberger AB.

CNS Oncol. 2016 Jul;5(3):175-86. doi: 10.2217/cns-2016-0009. Epub 2016 May 26. Review.

9.

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.

Maxwell R, Jackson CM, Lim M.

Curr Treat Options Oncol. 2017 Aug;18(8):51. doi: 10.1007/s11864-017-0492-y. Review.

PMID:
28785997
10.

Current clinical development of PI3K pathway inhibitors in glioblastoma.

Wen PY, Lee EQ, Reardon DA, Ligon KL, Alfred Yung WK.

Neuro Oncol. 2012 Jul;14(7):819-29. doi: 10.1093/neuonc/nos117. Epub 2012 May 22. Review.

11.

Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.

Coleman N, Ameratunga M, Lopez J.

Clin Med Insights Oncol. 2018 Feb 26;12:1179554918759079. doi: 10.1177/1179554918759079. eCollection 2018. Review.

12.

Bayesian adaptive randomized trial design for patients with recurrent glioblastoma.

Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM.

J Clin Oncol. 2012 Sep 10;30(26):3258-63. doi: 10.1200/JCO.2011.39.8420. Epub 2012 May 29.

13.

The changing landscape for the elimination of racial/ethnic health status disparities.

Walker B, Mays VM, Warren R.

J Health Care Poor Underserved. 2004 Nov;15(4):506-21.

14.

Epigenetic Targeting of Glioblastoma.

Romani M, Pistillo MP, Banelli B.

Front Oncol. 2018 Oct 16;8:448. doi: 10.3389/fonc.2018.00448. eCollection 2018. Review.

15.

Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma.

Tanguturi SK, Trippa L, Ramkissoon SH, Pelton K, Knoff D, Sandak D, Lindeman NI, Ligon AH, Beroukhim R, Parmigiani G, Wen PY, Ligon KL, Alexander BM.

Neuro Oncol. 2017 Jul 1;19(7):908-917. doi: 10.1093/neuonc/now312.

16.

Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2.

Alexander BM, Wen PY, Trippa L, Reardon DA, Yung WK, Parmigiani G, Berry DA.

Neuro Oncol. 2013 Aug;15(8):972-8. doi: 10.1093/neuonc/not088. Epub 2013 Jul 14. Review.

17.

Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data.

Shah N, Lankerovich M, Lee H, Yoon JG, Schroeder B, Foltz G.

BMC Genomics. 2013 Nov 22;14:818. doi: 10.1186/1471-2164-14-818.

18.

Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation.

Liu A, Hou C, Chen H, Zong X, Zong P.

Front Oncol. 2016 Jan 29;6:16. doi: 10.3389/fonc.2016.00016. eCollection 2016. Review.

19.

Glioblastoma: molecular analysis and clinical implications.

Huse JT, Holland E, DeAngelis LM.

Annu Rev Med. 2013;64:59-70. doi: 10.1146/annurev-med-100711-143028. Epub 2012 Oct 1.

PMID:
23043492
20.

Underutilization of radiation therapy in patients with glioblastoma: predictive factors and outcomes.

Aizer AA, Ancukiewicz M, Nguyen PL, Shih HA, Loeffler JS, Oh KS.

Cancer. 2014 Jan 15;120(2):238-43. doi: 10.1002/cncr.28398. Epub 2013 Oct 2.

Supplemental Content

Support Center